Proinflammatory and anti-inflammatory cytokines present in the acute phase of experimental colitis treated with saccharomyces boulardii

Digestive Diseases and Sciences

Volumn 55, Issue 9, 2010, Pages 2498-2504

  Grijó, Nathália Nahas ^a   Borra, Ricardo Carneiro ^b   Sdepanian, Vera Lucia ^a,c  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b SÃO LEOPOLDO MANDIC INSTITUTE AND RESEARCH CENTER   (Brazil)

^c NONE   (Brazil)

Author keywords

Animal models; Colitis; Cytokines; Probiotic; Saccharomyces boulardii; Trinitrobenzene sulfonic acid

Indexed keywords

CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; PROBIOTIC AGENT; TRANSFORMING GROWTH FACTOR BETA; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; COLON; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL TEST; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SACCHAROMYCES BOULARDII; SERUM;

ACUTE DISEASE; ANIMALS; COLITIS; COLON; CYTOKINES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; INFLAMMATION MEDIATORS; INTERLEUKIN-10; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; PROBIOTICS; RATS; RATS, WISTAR; SACCHAROMYCES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77956186573     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-009-1072-1     Document Type: Article

References (33)

1. CO Elson RB Sartor G Tennyson R Riddel 1995 Experimental models of IBD Gastroenterology 109 1344 1367 10.1016/0016-5085(95)90599-5 1:STN:280: DyaK28%2FivFensw%3D%3D 7557106
2. RB Sartor 1997 Review article: how relevant to human inflammatory bowel disease are current animal models of intestinal inflammation? Aliment Pharmacol Ther 11 S3 89 97 9467983
3. RS Blumberg LJ Saubermann W Strober 1999 Animal models of mucosal inflammation and their relation to human inflammatory bowel disease Curr Opin Immunol 11 648 656 10.1016/S0952-7915(99)00032-1 1:CAS:528:DyaK1MXnvFKmt78%3D 10631550
4. GP Morris PL Beck MS Heridge WT Depew MR Szewczuk JL Wallace 1989 Hapten-induced models of chronic inflammation and ulceration in the rat colon Gastroenterology 96 795 803 1:STN:280:DyaL1M7itFeqtQ%3D%3D 2914642
5. ME Cabezas J Gálvez MD Lorente A Concha D Camuesco S Azzouz A Osuna L Redondo A Zarzuelo 2002 Dietary fiber down- regulates colonic tumor necrosis factor α and nitric oxide production in trinitrobenzenesulfonic acid-induced colitic rats J Nutr 132 3263 3271
6. C Cherbut C Michel G Lecannu 2003 The prebiotic characteristics of fructooligosaccharides are necessary for reduction of TNBS-induced colitis in rats J Nutr 133 21 27 1:CAS:528:DC%2BD3sXjslejtg%3D%3D 12514261
7. L Peran D Camuesco M Comalada A Nieto M Concha MPD Ropero M Olivares J Xaus A Zarzuelo J Galvez 2005 Preventative effects of a probiotic, Lactobacillus salivarius ssp. Salivarius, in the TNBS model of rat colitis World J Gastroenterol 11 5185 5192 16127750
8. CM Surawicz GW Elmer P Speelman LV McFarland J Chinn G Van Belle 1989 Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study Gastroenterology 96 981 988 1:STN:280:DyaL1M7ntFyltQ%3D%3D 2494098
9. LV McFarland CM Surawicz RN Greenberg GW Elmer KA Moyer SA Melcher KE Bowen JL Cox 1995 Prevention of β-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo Am J Gastroenterol 90 439 448 1:STN:280:DyaK2M7nslWhtA%3D%3D 7872284
10. LV McFarland CM Surawicz RN Greenberg R Fekety GW Elmer KA Moyer SA Melcher KE Bowen JL Cox Z Noorani, et al. 1994 A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease JAMA 271 1913 1918 10.1001/jama.271.24.1913 1:STN:280:DyaK2c3mtVKksQ%3D%3D 8201735 (Pubitemid 24177098)
11. CM Surawicz LV McFarland RN Greenberg M Rubin R Fekety ME Mulligan RJ Garcia S Brandmarker K Bowen D Borjal GW Elmer 2000 The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii Clin Infect Dis 31 1012 1017 10.1086/318130 1:CAS:528:DC%2BD3cXos1yrt78%3D 11049785 (Pubitemid 32299362)
12. JP Buts G Corthier M Delmee 1993 Saccharomyces boulardii for Clostridium difficile-associated enteropathies in infants J Pediatr Gastroenterol Nutr 16 419 425 10.1097/00005176-199305000-00013 1:STN:280:DyaK3szgtFyjsA%3D%3D 8315551
13. Z Kurugöl G Koturoglu 2005 Effects of Saccharomyces boulardii in children with acute diarrhea Acta Paediatr 94 44 47 10.1080/08035250410022521 15858959 (Pubitemid 40127932)
14. H Kollaritsch H Holst P Grobara G Wiedermann 1993 Prevention of traveler's diarrhea with Saccharomyces boulardii. Results of a placebo-controlled double-blind study Fortschr Med 111 152 156 1:STN:280:DyaK3s3lt1ehug%3D%3D 8486328
15. G Bléichner H Blehaut H Mentec D Moyse 1997 Saccharomyces boulardii prevents diarrhea in critically ill tube-fed patients. A multicenter, randomized, double-blind placebo-controlled trial Intensive Care Med 23 517 523 10.1007/s001340050367 9201523 (Pubitemid 27263063)
16. M Guslandi G Mezzi M Sorghi PA Testoni 2000 Saccharomyces boulardii in maintenance treatment of Crohn's disease Dig Dis Sci 45 1462 1464 10.1023/A:1005588911207 1:STN:280:DC%2BD3cvislamsA%3D%3D 10961730 (Pubitemid 30636526)
17. M Guslandi P Giollo PA Testoni 2003 A pilot trial of Saccharomyces boulardii in ulcerative colitis Eur J Gastroenterol Hepatol 15 697 698 10.1097/00042737-200306000-00017 12840682 (Pubitemid 36688235)
18. SK Lee HJ Kim SG Chi YW Kim 2006 Saccharomyces boulardii ameliorates trinitrobenzenesulphonic acid-induced experimental colitis in rats: attenuation of pro-inflammatory gene expression Gastrointest Endosc 63 AB 222
19. G Dalmasso F Cottrez V Imbert P Lagadec JF Peyron P Rampal D Czerucka H Groux A Foussat V Brun 2006 Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes Gastroenterology 131 1812 1825 10.1053/j.gastro.2006.10.001 1:CAS:528:DC%2BD2sXhtFyltb8%3D 17087945 (Pubitemid 46001395)
20. G Rogler T Andus 1998 Cytokines in Inflammatory bowel disease World J Surg 22 382 389 10.1007/s002689900401 1:STN:280:DyaK1c7osVWhsA%3D%3D 9523521 (Pubitemid 28113526)
21. N Osman D Adawi D Adawi FRCSI S Ahrne B Jeppsson G Molin 2004 Modulation of the effects of dextran sulfate sodium-induced acute colitis by the administration of different probiotic strains of Lactobacillus and Bifidobacterium Dig Dis Sci 49 320 327 10.1023/B:DDAS.0000017459.59088.43 1:CAS:528:DC%2BD2cXhsFOhurw%3D 15104378 (Pubitemid 38392238)
22. IJ Fuss M Boirivant B Lacy W Strober 2002 The interrelated roles of TGF-β and IL-10 in the regulation of experimental colitis J.Immunol 168 900 908 1:CAS:528:DC%2BD38XksFWrtw%3D%3D 11777988
23. MI Torres M Garcia-Martin MI Fernandez N Nieto A Gil A Rios 1999 Experimental colitis induced by trinitrobenzenesulfonic acid: an ultrastructural and histochemical study Dig Dis Sci 44 2523 2529 10.1023/A:1026651408998 1:STN:280:DC%2BD3c%2FpsVajsQ%3D%3D 10630507
24. F Lamine H Eutamene J Fioramonti L Bueno V Theodorou 2004 Colonic responses to Lactobacillus farciminis treatment in trinitrobenzene sulphonic acid-induced colitis in rats Scand J Gastroenterol 39 1250 1258 10.1080/00365520410007953 1:STN:280:DC%2BD2M7ht1Gjsg%3D%3D 15743003 (Pubitemid 39656841)
25. B Foligné S Nutten L Steidler V Dennin D Goudercourt A Mercenier B Pot 2006 Recommendations for improved use of the murine TNBS-induced colitis model in evaluating anti-inflammatory properties of lactic acid bacteria: technical and microbiological aspects Dig Dis Sci 51 390 400 10.1007/s10620-006-3143-x 16534687
26. K Sugimoto H Hanai K Tozawa T Aoshi M Uchijima T Nagata Y Koide 2002 Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice Gastroenterology 123 1912 1922 10.1053/gast.2002.37050 1:CAS:528:DC%2BD38Xps1yktbk%3D 12454848 (Pubitemid 35408315)
27. V Coeuret M Gueguen JP Vernoux 2004 Numbers and strains of lactobacilli in some probiotic products Int J Food Microbiol 97 147 156 10.1016/j. ijfoodmicro.2004.04.015 15541801 (Pubitemid 39482378)
28. H Szajewska M Setty J Mrukowicz S Guandalini 2006 Probiotics in gastrointestinal diseases in children: hard and not-so-hard evidence of efficacy J Pediatr Gastroenterol Nutr 42 454 475 10.1097/01.mpg.0000221913.88511.72 16707966 (Pubitemid 43804722)
29. FJ Penna LA Filho AC Calçado HR Junior JR Nicolli 2000 Up-to-date clinical and experimental basis for the use of probiotics J Pediatr (Rio J) 76 Suppl 1 S209 S217
30. E Isolauri PV Kirjavainen S Salminen 2002 Probiotics: a role in the treatment of intestinal infection and inflammation? Gut 50 Suppl 3 III54 III59 10.1136/gut.50.suppl-3.iii54 11953334
31. MF Neurath I Fuss BL Kelsall DH Presky W Waegell W Strober 1996 Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance J Exp Med 183 2605 2616 10.1084/jem.183.6.2605 1:CAS:528:DyaK28Xjslaitr4%3D 8676081 (Pubitemid 26192369)
32. JJ Mulsow RW Watson JM Fitzpatrick PR O'Connell 2005 Transforming growth factor-beta promotes pro-fibrotic behavior by serosal fibroblasts via PKC and ERK1/2 mitogen activated protein kinase cell signaling Ann Surg 242 880 889 10.1097/01.sla.0000189606.58343.cd 16327498 (Pubitemid 41714066)
33. I Monteleone F Pallone G Monteleone 2009 Interleukin-23 and Th17 cells in the control of gut inflammation Mediators Inflamm 2009 297645 10.1155/2009/297645 19503799